LU92701I2 - Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive - Google Patents

Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive Download PDF

Info

Publication number
LU92701I2
LU92701I2 LU92701C LU92701C LU92701I2 LU 92701 I2 LU92701 I2 LU 92701I2 LU 92701 C LU92701 C LU 92701C LU 92701 C LU92701 C LU 92701C LU 92701 I2 LU92701 I2 LU 92701I2
Authority
LU
Luxembourg
Prior art keywords
pasireotide
hydrate
leads
occur
pharmaceutically acceptable
Prior art date
Application number
LU92701C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34593737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92701(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0326602A external-priority patent/GB0326602D0/en
Priority claimed from GB0406241A external-priority patent/GB0406241D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU92701I2 publication Critical patent/LU92701I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
LU92701C 2003-11-14 2015-04-29 Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive LU92701I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0326602A GB0326602D0 (en) 2003-11-14 2003-11-14 Organic compounds
GB0406241A GB0406241D0 (en) 2004-03-19 2004-03-19 Organic compounds
PCT/EP2004/012870 WO2005046645A1 (fr) 2003-11-14 2004-11-12 Composition pharmaceutique

Publications (1)

Publication Number Publication Date
LU92701I2 true LU92701I2 (fr) 2015-11-02

Family

ID=34593737

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92701C LU92701I2 (fr) 2003-11-14 2015-04-29 Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive

Country Status (31)

Country Link
US (3) US7759308B2 (fr)
EP (1) EP1686964B9 (fr)
JP (1) JP4682145B2 (fr)
KR (1) KR101233892B1 (fr)
AR (1) AR047310A1 (fr)
AT (1) ATE455537T1 (fr)
AU (1) AU2004289055C1 (fr)
BR (1) BRPI0416227B8 (fr)
CA (1) CA2541944C (fr)
CY (2) CY1110293T1 (fr)
DE (1) DE602004025271D1 (fr)
DK (1) DK1686964T3 (fr)
EC (1) ECSP066565A (fr)
ES (1) ES2339026T3 (fr)
HK (1) HK1093682A1 (fr)
HR (1) HRP20100190T1 (fr)
IL (1) IL175286A (fr)
IS (1) IS8480A (fr)
LU (1) LU92701I2 (fr)
MA (1) MA28155A1 (fr)
MX (1) MXPA06005357A (fr)
MY (1) MY158342A (fr)
NO (2) NO337172B1 (fr)
NZ (1) NZ546788A (fr)
PE (1) PE20050581A1 (fr)
PL (1) PL1686964T3 (fr)
PT (1) PT1686964E (fr)
RU (1) RU2404749C2 (fr)
SI (1) SI1686964T1 (fr)
TW (1) TWI295178B (fr)
WO (1) WO2005046645A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
ES2755032T3 (es) * 2005-12-22 2020-04-21 Novartis Ag Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
AR066677A1 (es) * 2007-05-24 2009-09-02 Novartis Ag Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas.
EP2247282B1 (fr) * 2008-01-30 2014-08-20 Novartis AG Préparation à libération soutenue comprenant de l'octréotide et trois polymères linéaires polylactide-co-glycolide
WO2009123903A1 (fr) * 2008-04-03 2009-10-08 Zymogenetics, Inc. Microsphères hémostatiques
JP5721624B2 (ja) 2008-07-08 2015-05-20 ノバルティス アーゲー 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2010123574A1 (fr) 2009-04-23 2010-10-28 Atrp Solutions Inc Macromolécules en étoile pour soins d'hygiène personnelle et soins domestiques
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
WO2013131879A1 (fr) 2012-03-07 2013-09-12 Novartis Ag Nouvelle application pour la pasireotide
CN105189643B (zh) 2012-08-30 2019-01-15 派诺聚合物技术公司 用于水力压裂液的双重机制增稠剂
MX2015009938A (es) 2013-02-04 2015-10-05 Atrp Solutions Inc Macromoleculas en forma de estrella tolerantes a las sales.
CA2903769A1 (fr) 2013-03-11 2014-10-09 Durect Corporation Composition injectable a liberation controlee comprenant un vehicule liquide a haute viscosite
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
CA2956431C (fr) 2014-07-03 2023-01-31 ATRP Solutions, Inc. Macromolecules en etoile compatibles avec un agent tensio-actif

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
WO1998032423A1 (fr) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Microspheres a liberation prolongee, leur production et utilisation
EP1240896A3 (fr) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation de peptides hydrosolubles
ES2185373T3 (es) * 1998-07-23 2003-04-16 Sod Conseils Rech Applic Encapsulacion de peptidos solubles en agua.
WO2000004916A1 (fr) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation de peptides hydrosolubles
NZ526127A (en) 1999-08-18 2005-02-25 Sod Conseils Rech Applic Use of a somatostatin analog in the manufacture of a medicament
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP4679822B2 (ja) * 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
TWI295178B (en) 2008-04-01
DE602004025271D1 (de) 2010-03-11
IL175286A0 (en) 2006-09-05
TW200529883A (en) 2005-09-16
NO337172B1 (no) 2016-02-01
EP1686964B1 (fr) 2010-01-20
KR20060115873A (ko) 2006-11-10
MA28155A1 (fr) 2006-09-01
CA2541944C (fr) 2014-02-25
WO2005046645A1 (fr) 2005-05-26
PE20050581A1 (es) 2005-09-09
RU2006120484A (ru) 2007-12-27
HK1093682A1 (en) 2007-03-09
DK1686964T3 (da) 2010-05-17
CY2015011I2 (el) 2016-04-13
US20100272809A1 (en) 2010-10-28
BRPI0416227B1 (pt) 2019-06-18
ECSP066565A (es) 2006-10-17
AR047310A1 (es) 2006-01-18
AU2004289055C1 (en) 2009-05-21
ATE455537T1 (de) 2010-02-15
NO2016003I1 (no) 2016-02-02
MY158342A (en) 2016-09-30
JP2007511482A (ja) 2007-05-10
IS8480A (is) 2006-05-23
US8188037B2 (en) 2012-05-29
RU2404749C2 (ru) 2010-11-27
EP1686964A1 (fr) 2006-08-09
PL1686964T3 (pl) 2010-06-30
ES2339026T3 (es) 2010-05-14
MXPA06005357A (es) 2006-07-10
SI1686964T1 (sl) 2010-05-31
IL175286A (en) 2012-05-31
NZ546788A (en) 2009-12-24
NO20062777L (no) 2006-08-14
JP4682145B2 (ja) 2011-05-11
US7759308B2 (en) 2010-07-20
CY1110293T1 (el) 2015-01-14
AU2004289055A1 (en) 2005-05-26
HRP20100190T1 (hr) 2010-06-30
BRPI0416227A (pt) 2007-01-02
US20120214749A1 (en) 2012-08-23
CA2541944A1 (fr) 2005-05-26
NO2016003I2 (no) 2016-02-02
KR101233892B1 (ko) 2013-02-18
CY2015011I1 (el) 2016-04-13
AU2004289055B2 (en) 2008-10-30
PT1686964E (pt) 2010-02-04
BRPI0416227B8 (pt) 2021-05-25
EP1686964B9 (fr) 2010-08-04
US20070212418A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
LU92701I2 (fr) Pasiréotide ou un sel pharmaceutiquement acceptable qui en dérive ou un hydrate qui en dérive
LU92684I2 (fr) Fidaxomicine ou son sel pharmaceutiquement acceptable
LU92702I2 (fr) Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
LU92883I2 (fr) Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive
LU92678I2 (fr) Tobramycine ou un sel pharmaceutiquement acceptable qui en dérive
NO2013008I1 (no) Krizotinib eller et farmasøytisk akseptabelt salt,hydrat eller solvat derav
DK1704324T3 (da) Leddelt falsk havbund
DE50307359D1 (de) Mehrdecksiebmaschine
DE60317391D1 (de) Verbinder
SE0203705L (sv) Vinkelhake
DE60335913D1 (de) Ghrelin-analoga
DE60301239D1 (de) Verbinder
NO20042118L (no) Halvt neddykkbar offshoreplattform
DE60208885D1 (de) Verbinder
DE60315937D1 (de) Verbinder
AP2004003156A0 (en) Peptide deformylase inhibitors.
DE60330377D1 (de) Giessgefäss
DE60223352D1 (de) Verbinder
ITMI20022022A1 (it) Analoghi di nocicettina.
DE60218623D1 (de) Verbinder
DE10301279B8 (de) Verbinder
ITTO20020045A0 (it) Giubbotto per immersione.
DE60312105D1 (de) Verbinder
NO20021944D0 (no) Fartöy
ITTO20020044A0 (it) Giubbotto per immersione.